$XSNX
NovAccess Global Inc

2024 Q4 Form 10-Q Financial Statement

#000118518524001053 Filed on October 31, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q2 2023 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue $0.00 $0.00
YoY Change
Gross Profit $0.00 $0.00
YoY Change
Gross Profit Margin
Selling, General & Admin $278.0K $371.8K
YoY Change -37.44% 50.9%
% of Gross Profit
Research & Development $37.30K $38.20K
YoY Change -7.13% -18.83%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $315.3K $410.0K
YoY Change -34.93% 39.72%
Operating Profit -$315.3K -$410.0K
YoY Change -34.93%
Interest Expense -$1.337M
YoY Change -211.72%
% of Operating Profit
Other Income/Expense, Net -$621.0K -$20.75K
YoY Change 110.51% -97.84%
Pretax Income -$1.768M
YoY Change 2960.37%
Income Tax
% Of Pretax Income
Net Earnings -$936.3K -$1.768M
YoY Change 20.1% 2960.37%
Net Earnings / Revenue
Basic Earnings Per Share -$0.02
Diluted Earnings Per Share -$0.02 -$0.08
COMMON SHARES
Basic Shares Outstanding 61.91M shares 44.60M shares 21.54M shares
Diluted Shares Outstanding 54.12M shares

Balance Sheet

Concept 2024 Q4 2024 Q2 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $21.42K
YoY Change -66.66%
Cash & Equivalents $794.00 $21.42K
Short-Term Investments
Other Short-Term Assets $40.83K
YoY Change -32.68%
Inventory
Prepaid Expenses $50.83K $40.83K
Receivables
Other Receivables
Total Short-Term Assets $51.63K $62.25K
YoY Change -70.84% -50.16%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $221.9K $0.00
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $221.9K -$2.00
YoY Change -7397833.33% -300.0%
TOTAL ASSETS
Total Short-Term Assets $51.63K $62.25K
Total Long-Term Assets $221.9K -$2.00
Total Assets $273.6K $62.25K
YoY Change 54.53% -50.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $738.8K $514.7K
YoY Change 41.97% 37.0%
Accrued Expenses $33.80K $300.3K
YoY Change 30.91% 204.45%
Deferred Revenue
YoY Change
Short-Term Debt $34.00K $21.00K
YoY Change 61.9% 68.0%
Long-Term Debt Due $2.166M
YoY Change 71.03%
Total Short-Term Liabilities $7.699M $7.861M
YoY Change 20.11% 64.52%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $7.699M $7.861M
Total Long-Term Liabilities $0.00
Total Liabilities $7.699M $7.861M
YoY Change 20.11% 64.52%
SHAREHOLDERS EQUITY
Retained Earnings -$67.03M -$66.90M
YoY Change 2.91% 7.6%
Common Stock $49.42M $49.02M
YoY Change 13.2% 13.4%
Preferred Stock $4.747M $4.747M
YoY Change 0.0% 0.0%
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$7.425M -$7.798M
YoY Change
Total Liabilities & Shareholders Equity $273.6K $62.25K
YoY Change 54.53% -50.16%

Cashflow Statement

Concept 2024 Q4 2024 Q2 2023 Q3
OPERATING ACTIVITIES
Net Income -$936.3K -$1.768M
YoY Change 20.1% 2960.37%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$154.9K
YoY Change -21.61%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 114.8K
YoY Change -33.2%
NET CHANGE
Cash From Operating Activities -154.9K
Cash From Investing Activities
Cash From Financing Activities 114.8K
Net Change In Cash -40.05K
YoY Change 55.9%
FREE CASH FLOW
Cash From Operating Activities -$154.9K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 us-gaap Guarantee Obligations Current Carrying Value
GuaranteeObligationsCurrentCarryingValue
1042500 usd
dei Entity Registrant Name
EntityRegistrantName
NovAccess Global Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
CO
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-1384159
dei Security12b Title
Security12bTitle
None
CY2024Q2 us-gaap Guarantee Obligations Current Carrying Value
GuaranteeObligationsCurrentCarryingValue
1301835 usd
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Entity File Number
EntityFileNumber
000-29621
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Address Address Line1
EntityAddressAddressLine1
8584 E. Washington Street #127
dei Entity Address City Or Town
EntityAddressCityOrTown
Chagrin Falls
dei Entity Address State Or Province
EntityAddressStateOrProvince
OH
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
44023
dei City Area Code
CityAreaCode
213
dei Local Phone Number
LocalPhoneNumber
642-9268
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
61906932 shares
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
794 usd
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21415 usd
CY2024Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
50833 usd
CY2023Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
40833 usd
CY2024Q2 us-gaap Assets Current
AssetsCurrent
51627 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
62248 usd
CY2024Q2 us-gaap Equity Method Investments
EquityMethodInvestments
221932 usd
CY2023Q3 us-gaap Equity Method Investments
EquityMethodInvestments
0 usd
CY2024Q2 us-gaap Assets
Assets
273559 usd
CY2023Q3 us-gaap Assets
Assets
62248 usd
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
738756 usd
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
514686 usd
CY2024Q2 us-gaap Interest Payable Current
InterestPayableCurrent
2782570 usd
CY2023Q3 us-gaap Interest Payable Current
InterestPayableCurrent
1982567 usd
CY2024Q2 us-gaap Derivative Liabilities
DerivativeLiabilities
1901735 usd
CY2023Q3 us-gaap Derivative Liabilities
DerivativeLiabilities
2982382 usd
CY2024Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
181217 usd
CY2023Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
181217 usd
CY2024Q2 us-gaap Short Term Borrowings
ShortTermBorrowings
34000 usd
CY2023Q3 us-gaap Short Term Borrowings
ShortTermBorrowings
21000 usd
CY2024Q2 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
134126 usd
CY2023Q3 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
0 usd
CY2024Q2 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
2039003 usd
CY2023Q3 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
2166380 usd
CY2024Q2 us-gaap Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
0 usd
CY2023Q3 us-gaap Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
0 usd
CY2024Q2 us-gaap Notes Payable Current
NotesPayableCurrent
21500 usd
CY2023Q3 us-gaap Notes Payable Current
NotesPayableCurrent
12500 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
7698781 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
7860732 usd
CY2024Q2 us-gaap Liabilities
Liabilities
7698781 usd
CY2023Q3 us-gaap Liabilities
Liabilities
7860732 usd
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
6 usd
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
6 usd
CY2024Q2 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2023Q3 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
2000000000 shares
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
2000000000 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
61906932 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
61906932 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21744209 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21744209 shares
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
44083357 usd
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
43683197 usd
CY2024Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
5339846 usd
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
5335398 usd
CY2024Q2 xsnx Additional Paid In Capital Common Stock Warrants
AdditionalPaidInCapitalCommonStockWarrants
5432261 usd
CY2023Q3 xsnx Additional Paid In Capital Common Stock Warrants
AdditionalPaidInCapitalCommonStockWarrants
5338273 usd
CY2024Q2 us-gaap Additional Paid In Capital Preferred Stock
AdditionalPaidInCapitalPreferredStock
4747108 usd
CY2023Q3 us-gaap Additional Paid In Capital Preferred Stock
AdditionalPaidInCapitalPreferredStock
4747108 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-67027800 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-66902466 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-7425222 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-7798484 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
273559 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
62248 usd
CY2024Q2 us-gaap Revenues
Revenues
0 usd
CY2023Q2 us-gaap Revenues
Revenues
0 usd
us-gaap Revenues
Revenues
0 usd
us-gaap Revenues
Revenues
0 usd
CY2024Q2 us-gaap Cost Of Revenue
CostOfRevenue
0 usd
CY2023Q2 us-gaap Cost Of Revenue
CostOfRevenue
0 usd
us-gaap Cost Of Revenue
CostOfRevenue
0 usd
us-gaap Cost Of Revenue
CostOfRevenue
0 usd
CY2024Q2 us-gaap Gross Profit
GrossProfit
0 usd
CY2023Q2 us-gaap Gross Profit
GrossProfit
0 usd
us-gaap Gross Profit
GrossProfit
0 usd
us-gaap Gross Profit
GrossProfit
0 usd
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
37301 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
40164 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
123273 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
116164 usd
CY2024Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
278048 usd
CY2023Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
444481 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
682177 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1940587 usd
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
315349 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
484645 usd
us-gaap Operating Expenses
OperatingExpenses
805450 usd
us-gaap Operating Expenses
OperatingExpenses
2056751 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-315349 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-484645 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-805450 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-2056751 usd
CY2024Q2 us-gaap Other Income
OtherIncome
15379 usd
CY2023Q2 us-gaap Other Income
OtherIncome
56082 usd
us-gaap Other Income
OtherIncome
15379 usd
us-gaap Other Income
OtherIncome
56082 usd
CY2024Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-445550 usd
CY2023Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
78871 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
1288086 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-38120 usd
CY2024Q2 us-gaap Gains Losses On Restructuring Of Debt
GainsLossesOnRestructuringOfDebt
-5085 usd
CY2023Q2 us-gaap Gains Losses On Restructuring Of Debt
GainsLossesOnRestructuringOfDebt
-134875 usd
us-gaap Gains Losses On Restructuring Of Debt
GainsLossesOnRestructuringOfDebt
-259335 usd
us-gaap Gains Losses On Restructuring Of Debt
GainsLossesOnRestructuringOfDebt
-60750 usd
CY2024Q2 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
185728 usd
CY2023Q2 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
295072 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
364014 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
857742 usd
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-620984 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-294994 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
680116 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-900530 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-936333 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-779639 usd
us-gaap Net Income Loss
NetIncomeLoss
-125334 usd
us-gaap Net Income Loss
NetIncomeLoss
-2957281 usd
CY2024Q2 us-gaap Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount
WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount
0 usd
CY2023Q2 us-gaap Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount
WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount
0 usd
us-gaap Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount
WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount
0 usd
us-gaap Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount
WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount
44241 usd
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-936333 usd
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-779639 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-125334 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3001522 usd
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.04
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.15
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.04
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.15
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54121935 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21209938 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35225010 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20290280 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54121935 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21209938 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35225010 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20290280 shares
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-4653066 usd
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
282665 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
50000 usd
us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
82500 usd
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments
StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments
12000 usd
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
563314 usd
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
386912 usd
us-gaap Net Income Loss
NetIncomeLoss
-2957281 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-6232956 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-7798484 usd
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
7871 usd
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments
StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments
156607 usd
us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
13750 usd
us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
221932 usd
us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
4448 usd
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
93988 usd
us-gaap Net Income Loss
NetIncomeLoss
-125334 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-7425222 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-5726692 usd
CY2023Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
22963 usd
CY2023Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments
StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments
12000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
238412 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-779639 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-6232956 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-6853896 usd
CY2024Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
1712 usd
CY2024Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments
StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments
61685 usd
CY2024Q2 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
13750 usd
CY2024Q2 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
221932 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
940 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
64988 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-936333 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-7425222 usd
us-gaap Net Income Loss
NetIncomeLoss
-125334 usd
us-gaap Net Income Loss
NetIncomeLoss
-2957281 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
114844 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
638481 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
1288086 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-38120 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
93988 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
386912 usd
xsnx Imputed Interest On Related Party Loan
ImputedInterestOnRelatedPartyLoan
4448 usd
xsnx Imputed Interest On Related Party Loan
ImputedInterestOnRelatedPartyLoan
0 usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
7871 usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
282665 usd
us-gaap Share Based Compensation
ShareBasedCompensation
0 usd
us-gaap Share Based Compensation
ShareBasedCompensation
563314 usd
us-gaap Debt Related Commitment Fees And Debt Issuance Costs
DebtRelatedCommitmentFeesAndDebtIssuanceCosts
13750 usd
us-gaap Debt Related Commitment Fees And Debt Issuance Costs
DebtRelatedCommitmentFeesAndDebtIssuanceCosts
82500 usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
0 usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
65979 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
10000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-11067 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
228541 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
144663 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
800003 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
405752 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-159975 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-469786 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
50000 usd
us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
13000 usd
us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
0 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
230514 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
599250 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
9000 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
0 usd
us-gaap Payments For Repurchase Of Preferred Stock And Preference Stock
PaymentsForRepurchaseOfPreferredStockAndPreferenceStock
0 usd
us-gaap Payments For Repurchase Of Preferred Stock And Preference Stock
PaymentsForRepurchaseOfPreferredStockAndPreferenceStock
5000 usd
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
113160 usd
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
177250 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
139354 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
467000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-20621 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-2786 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21415 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
64251 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
794 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
61464 usd
us-gaap Interest Paid Net
InterestPaidNet
15505 usd
us-gaap Interest Paid Net
InterestPaidNet
192878 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
156607 usd
us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
12000 usd
xsnx Initial Derivative Recognition On New Loans And Warrants
InitialDerivativeRecognitionOnNewLoansAndWarrants
207439 usd
xsnx Initial Derivative Recognition On New Loans And Warrants
InitialDerivativeRecognitionOnNewLoansAndWarrants
588147 usd
us-gaap Stock Issued During Period Value Purchase Of Assets
StockIssuedDuringPeriodValuePurchaseOfAssets
221932 usd
us-gaap Stock Issued During Period Value Purchase Of Assets
StockIssuedDuringPeriodValuePurchaseOfAssets
0 usd
us-gaap Stock Issued1
StockIssued1
13750 usd
us-gaap Stock Issued1
StockIssued1
82500 usd
CY2020Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-1,000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration:underline">Use of Estimates</span></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the accompanying consolidated financial statements. Significant estimates made in preparing these consolidated financial statements include the estimate of the deferred tax valuation allowance, the fair value of stock options, warrants, and derivative liabilities. Actual results could differ from those estimates.</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-936333 usd
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-779639 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-125334 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3001522 usd
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54121935 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21209938 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35225010 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20290280 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54121935 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21209938 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35225010 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20290280 shares
CY2024Q2 us-gaap Derivative Assets
DerivativeAssets
0 usd
CY2023Q3 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
2253391 usd
CY2023Q3 us-gaap Embedded Derivative Fair Value Of Embedded Derivative Liability
EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
728991 usd
CY2023Q3 us-gaap Derivative Assets Liabilities At Fair Value Net
DerivativeAssetsLiabilitiesAtFairValueNet
2982382 usd
CY2024Q2 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
1766561 usd
CY2024Q2 us-gaap Embedded Derivative Fair Value Of Embedded Derivative Liability
EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
135174 usd
CY2024Q2 us-gaap Derivative Assets Liabilities At Fair Value Net
DerivativeAssetsLiabilitiesAtFairValueNet
1901735 usd
CY2022Q3 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
1440012 usd
CY2023 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Issues
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues
813711 usd
CY2023 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Gain Loss Included In Earnings
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings
728659 usd
CY2023Q3 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
2982382 usd
us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Issues
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues
207439 usd
us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Gain Loss Included In Earnings
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings
-1288086 usd
CY2024Q2 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
1901735 usd
CY2024Q2 us-gaap Equity Method Investments
EquityMethodInvestments
221932 usd
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
2000000000 shares
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
us-gaap Stock Issued During Period Shares Period Increase Decrease
StockIssuedDuringPeriodSharesPeriodIncreaseDecrease
40162723 shares
us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
22241012 shares
us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
626256 shares
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
7871 usd
CY2024Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
2500000 shares
us-gaap Stock Issued During Period Shares Period Increase Decrease
StockIssuedDuringPeriodSharesPeriodIncreaseDecrease
2865950 shares
us-gaap Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
141677 shares
us-gaap Stock Issued During Period Shares Other
StockIssuedDuringPeriodSharesOther
500000 shares
CY2024Q2 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
2173129 usd
CY2024Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
134126 usd
CY2024Q2 us-gaap Convertible Debt
ConvertibleDebt
2039003 usd
CY2022Q3 us-gaap Debt Instrument Maturity Date Description
DebtInstrumentMaturityDateDescription
The loan terms required repayment of all amounts outstanding under the loan on the earlier of: (a) October 31, 2022 or (b) the receipt by the Company of debt or equity financing of $3.0 million.
CY2022Q3 us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2022-10-31
CY2023Q1 us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
8500 usd
CY2023Q1 us-gaap Debt Instrument Maturity Date Description
DebtInstrumentMaturityDateDescription
the earlier of August 31, 2023, or our receipt of debt or equity financing of at least $3.0 million
xsnx Imputed Interest On Related Party Loan
ImputedInterestOnRelatedPartyLoan
4448 usd
CY2023Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1500000 shares
CY2023Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
44241 usd
CY2023Q2 xsnx Class Of Warrant Or Rights Granted
ClassOfWarrantOrRightsGranted
750000 shares
CY2023Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.0001
CY2023Q3 xsnx Class Of Warrant Or Rights Granted
ClassOfWarrantOrRightsGranted
2000000 shares
CY2023Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.2
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
177086 usd
CY2023Q4 xsnx Warrants And Rights Outstanding Term Increase
WarrantsAndRightsOutstandingTermIncrease
P2Y
CY2023Q4 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
29000 usd
CY2024Q2 us-gaap Embedded Derivative Fair Value Of Embedded Derivative Liability
EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
135174 usd
CY2023Q3 us-gaap Embedded Derivative Fair Value Of Embedded Derivative Liability
EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
728991 usd
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2000000 shares
CY2020Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
0.01
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0032 pure
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.46 pure
CY2020Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.175
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3542857 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0368 pure
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.4679 pure
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5542857 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.115
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
0 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5542857 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.115
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
33797 usd
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11154 usd
CY2024Q2 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
486066 usd
CY2023Q3 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
289101 usd
CY2024Q2 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
150712 usd
CY2023Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
3875 usd
CY2024Q2 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
717512 usd
CY2023Q3 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
571763 usd
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
40402 usd
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
40402 usd
CY2024Q2 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
52246 usd
CY2023Q3 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
23772 usd
CY2024Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2782570 usd
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1982567 usd
CY2022Q1 us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
1502670 shares
CY2022Q1 us-gaap Preferred Stock Convertible Conversion Price
PreferredStockConvertibleConversionPrice
0.35
CY2022Q1 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
525934 usd
CY2022Q1 xsnx Common Stock Outstanding Percentage
CommonStockOutstandingPercentage
0.10 pure
CY2022Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
250000 usd
CY2024Q2 us-gaap Payable Preferred Stock Redeemed
PayablePreferredStockRedeemed
95000 usd
ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Entity Central Index Key
EntityCentralIndexKey
0001039466
dei No Trading Symbol Flag
NoTradingSymbolFlag
true

Files In Submission

Name View Source Status
0001185185-24-001053-index-headers.html Edgar Link pending
0001185185-24-001053-index.html Edgar Link pending
0001185185-24-001053.txt Edgar Link pending
0001185185-24-001053-xbrl.zip Edgar Link pending
ex_737768.htm Edgar Link pending
ex_737769.htm Edgar Link pending
ex_737770.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
novaccess20240630_10q.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
novaccess20240630_10q_htm.xml Edgar Link completed
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
xsnx-20240630.xsd Edgar Link pending
xsnx-20240630_cal.xml Edgar Link unprocessable
xsnx-20240630_def.xml Edgar Link unprocessable
xsnx-20240630_lab.xml Edgar Link unprocessable
xsnx-20240630_pre.xml Edgar Link unprocessable